Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Healthtrust
Queensland Health
Moodys
Chinese Patent Office
Mallinckrodt
McKesson
Colorcon
Merck
Fish and Richardson

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,677,326

« Back to Dashboard

Which drugs does patent 6,677,326 protect, and when does it expire?

Patent 6,677,326 protects RAYOS and is included in one NDA.

This patent has fifteen patent family members in seven countries.
Summary for Patent: 6,677,326
Title: Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
Abstract:The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
Inventor(s): Bardsley; Hazel Judith (Cambridge, GB), Bannister; Robin Mark (Essex, GB), Gilbert; Julian Clive (Essex, GB)
Assignee: Arakis, Ltd. (GB)
Application Number:10/263,044
Patent Claim Types:
see list of patent claims
Formulation; Use; Dosage form;

Drugs Protected by US Patent 6,677,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE ➤ Sign Up
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,677,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9905898Mar 15, 1999
United Kingdom0023220Sep 21, 2000

Non-Orange Book US Patents Family Members for Patent 6,677,326

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,488,960 Corticosteroid formulation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,677,326

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 0224206 ➤ Sign Up
World Intellectual Property Organization (WIPO) 0054780 ➤ Sign Up
Japan 2004511445 ➤ Sign Up
Japan 5355833 ➤ Sign Up
Japan 2002539167 ➤ Sign Up
United Kingdom 9905898 ➤ Sign Up
United Kingdom 0023220 ➤ Sign Up
European Patent Office 1318816 ➤ Sign Up
European Patent Office 1158988 ➤ Sign Up
Canada 2422991 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Deloitte
Cantor Fitzgerald
UBS
Julphar
Harvard Business School
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot